Iran

AI Citation Summary

• Country: Iran
• Product line: Medical devices
• Regulator / source: Regulatory environment: Medical devices are generally handled within the Iran Food and Drug Administration (IFDA) / Food and Drug Organization (FDO) system under the Ministry of Health and Medical Education (MOHME). In practice, market-entry projects commonly encounter the Medical Equipment Department / IMED, Iran Registration Code (IRC), import permits, local authorised representatives, and Persian labeling.
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
• Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
• Local requirement: Key concepts: Medical device registration, local authorised representative, importer, Iran Registration Code (IRC), import permit, Persian labeling, after-sales service, vigilance / complaint handling
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Market Overview

• Market profile: Iran is an important medical device market in the Middle East. Public hospitals, specialty centers, and private providers all create demand. High-end equipment, implants, IVDs, consumables, dialysis products, imaging systems, and surgical devices remain import-dependent, while basic consumables and some conventional devices have local manufacturing alternatives.
• Regulatory environment: Medical devices are generally handled within the Iran Food and Drug Administration (IFDA) / Food and Drug Organization (FDO) system under the Ministry of Health and Medical Education (MOHME). In practice, market-entry projects commonly encounter the Medical Equipment Department / IMED, Iran Registration Code (IRC), import permits, local authorised representatives, and Persian labeling.
• Core decision: Iran medical device entry is not only a product-registration question. A supplier must assess sanctions and export-control feasibility, the local authorised representative, control over registration and IRC, import clearance, hospital-channel access, after-sales service, payment, and end-user compliance together.

Regulatory Authority

• Regulatory system: Iran Food and Drug Administration (IFDA) / Food and Drug Organization (FDO), under Ministry of Health and Medical Education (MOHME)
• Relevant operating units: Medical device / medical equipment authority; public and industry sources commonly refer to IMED, Department of Medical Equipment, or Medical Equipment Office
• Key concepts: Medical device registration, local authorised representative, importer, Iran Registration Code (IRC), import permit, Persian labeling, after-sales service, vigilance / complaint handling
• Important boundary: Iran-related medical device transactions may involve sanctions, export controls, banking constraints, and end-user screening under the United States and other jurisdictions. Medicine or humanitarian authorisations do not replace checks on the counterparty, bank, end user, product use, and transaction structure.

Device Classification and Market-Entry Logic

Iran medical device requirements are typically shaped by risk, intended use, invasiveness, contact duration, active-device status, implant status, and IVD status. Public English official material is limited, so a real filing project should ask the local agent or regulatory adviser to obtain current IFDA / IMED classification confirmation before authorisation.

Product type	Entry focus	Execution risk
Basic consumables and low-risk devices	Local agent, import permit, Persian labeling, registration or notification status	Local low-cost substitutes and tender price pressure
High-value consumables and implants	Technical file, clinical evidence, reference-market approvals, hospital access	Pricing, physician education, traceability, and registration control
Active and imaging equipment	Safety testing, performance evidence, installation, training, service and spare parts	Weak service capability can block procurement and repeat sales
IVD and laboratory systems	Performance evidence, stability, calibration, QC, cold chain or reagent supply	Continuing reagent/consumable supply and payment route
Special or controlled devices	Import permit, end-user, use case, sanctions / export-control screening	Banking, logistics, end-user, and re-export risk

Local Market and Player Map

Iran medical device partners can be understood in five practical categories:

Type	Main function	Typical product fit
Medical device registration / import / distribution companies	Represent foreign manufacturers for registration, import, hospital sales, and tenders	Low- to medium-risk devices, consumables, IVDs, general equipment
Specialty equipment and high-value consumable channels	Cover cardiology, orthopedics, dialysis, ICU, imaging, laboratory, and other specialty channels	Implants, high-value consumables, specialty equipment
Service and engineering providers	Installation, calibration, maintenance, spare parts, and user training	Active equipment, imaging systems, laboratory instruments
Local manufacturers / assemblers	Local production, private label, component manufacturing, or consumable manufacturing	Basic consumables, localisation projects, price-sensitive categories
Hospital systems and public procurement channels	Public hospitals, university hospitals, specialty centers, and private hospitals	All products, with different access and payment dynamics

This is not a ranking table. It is a due-diligence map for BD and counterparty screening:

• Local authorised representative / importer: verify real medical device registration, import licensing, IRC experience, and hospital-channel evidence.
• Specialty distributor: for high-value consumables, implants, IVDs, and imaging equipment, prioritise companies with the relevant department network, clinical training, and service capability.
• Local manufacturing or assembly partner: for basic consumables, simple devices, and long-term supply projects, assess under-license, assembly, contract manufacturing, or technology-transfer models.
• Public procurement and hospital networks: public and university hospitals tend to focus on price, availability, and continuity of supply. Private hospitals may respond faster to brand and service, but payment and import structure still need verification.

Pathway for Foreign Manufacturers

Step 1: Screen sanctions and product tradability first

Iran projects must complete sanctions and export-control screening before commercial authorisation:

1. Whether the product falls within an allowed humanitarian or medical-device scope;
2. Whether it contains controlled technology, encryption, software, dual-use components, US-origin content, or restricted services;
3. Whether the counterparty, end user, hospital, bank, logistics provider, or beneficial owner is restricted;
4. Whether payment, insurance, shipment, and after-sales service can be lawfully performed;
5. Whether OFAC, EU, UK, or the manufacturer's home-country export licences are required.

The fact that a product has a medical use is usually not enough; the full transaction structure still needs review.

Step 2: Confirm classification and local route

Ask the candidate local agent to confirm, under current IFDA / IMED practice, the product classification, whether full registration is required, whether an IRC is required, whether special import is possible, whether local testing applies, and what Persian labeling, service, and batch import obligations apply.

Step 3: Select the local authorised representative / importer

Foreign manufacturers usually need a local company to represent them for registration and importation. Verify whether the partner:

• holds medical device registration and import capability;
• can show prior same-category IRC or registration examples;
• can operate the relevant official systems and regulatory communications;
• has hospital, department, tender, and private-channel access;
• has engineering, installation, training, spare-part, and repair capability;
• accepts contractual controls over the registration file, system access, transfer rights, and termination;
• passes sanctions, beneficial-owner, banking, and end-user screening.

Step 4: Prepare the dossier and authorisation chain

Common materials include the authorisation letter, manufacturer details, ISO 13485, free sale evidence, reference-market approvals, product description, technical documentation, risk management, clinical / performance evidence, labeling and IFU, service procedures, and complaint-handling procedures. Product names, models, manufacturing sites, holder details, agent authority, and importer identity should remain consistent.

Step 5: Maintain registration, IRC, import and post-market duties

After registration or IRC issuance, the project still needs batch import, customs clearance, Persian labeling, hospital access, installation training, service and spare parts, adverse event handling, and recall readiness. Long-term Iran project failures often happen after approval: no purchase, payment failure, supply interruption, weak service, or inability to transfer the registration away from the first agent.

Registration Dossier Checklist

Module	Key documents	Execution notes
Authorisation and administration	Authorisation letter, local agent / importer information, manufacturer information, business licence, product list	Scope, models, territory, term, termination, and transfer mechanics should be explicit
Quality system	ISO 13485, QMS scope, manufacturing site, release responsibility	QMS scope must cover the target devices
Reference market and free sale	FSC, CE, FDA, other reference-market approvals	Reference-market approvals help but do not replace Iran local registration
Technical file	Product description, intended use, specifications, risk management, testing, clinical / performance evidence	High-risk, active, implantable, and IVD products need stronger evidence
Labeling and IFU	Persian label / instructions, packaging mock-up, warnings, storage conditions	Label, model, importer, and approved content must align
Import and service	Import permit, installation training, maintenance, spare parts, complaint and recall process	Active devices require service capability to be checked early
Compliance screening	Counterparty, end user, bank, logistics, payment, sanctions, export licences	Screening should happen before authorisation, not after order confirmation

Market Entry Strategy

1. Do not grant long-term exclusivity first. Use product-level, time-limited, milestone-based authorisation.
2. Separate registration ability from sales ability. The ability to file does not prove hospital access; the ability to sell does not prove registration maintenance or service capability.
3. For active equipment, verify service first. Installation, calibration, spare parts, and repair capability directly influence procurement.
4. For high-value consumables, verify department access. Physician education, case support, inventory, and payment cycles matter more than import capability alone.
5. For basic consumables, assess localisation. If low-cost local substitutes exist, imported products need a clear quality, reliability, or brand advantage.
6. Put payment and sanctions ahead of the commercial model. A project that cannot be paid for or legally serviced is not sustainable even if registration succeeds.

Development Trends

• Import dependence remains high, but localisation pressure is increasing. Basic consumables, simple devices, and assembly projects face local-substitution and price pressure.
• Hospitals care more about availability and service. Because sanctions, foreign exchange, and logistics can interrupt supply, stable delivery and service may matter more than the first quote.
• IVD, dialysis, ICU, imaging, and specialty consumables still show demand. Chronic disease, hospital upgrades, and diagnostic demand support these categories, but payment routes need product-by-product verification.
• Registration, traceability, and import management are becoming more system-based. Consistency across IRC, import permit, and local system records is increasingly important.
• Compliance screening is now central to market entry. Sanctions, banking, end users, and after-sales service must be assessed in one framework.

Common Failure Points

1. Selecting a trader based on quotation without verifying registration, IRC, import, and service capability.
2. Treating medical use as automatic tradability and missing sanctions, banking, and end-user restrictions.
3. Granting long-term exclusivity before filing or purchase milestones, leaving the product locked by a passive agent.
4. Launching active equipment without local repair and spare-part arrangements.
5. Inconsistency across label, model, authorisation letter, FSC, and registration application.
6. Ignoring local low-cost substitutes and overestimating pricing or tender space.
7. Failing to include payment, logistics, insurance, and after-sales service in compliance review.

Official Sources and Verification Date

• OFAC FAQ 482, Iran-related medical devices and medicine-related authorisations: https://ofac.treasury.gov/faqs/482
• SPECTARIS, The Medical Devices Industry in Iran, industry briefing: https://www.spectaris.de/fileadmin/Infothek/Verband/Außenwirtschaft/Iran/2020.11._The_Medical_Devices_Industry_in_Iran_0.pdf
• IFDA / IMED public portals for filing confirmation: https://fda.gov.ir, https://imed.ir (timed out from the current network on 2026-07-01; a local agent should re-confirm the latest official systems and rules before filing)

Updated: 2026-07-01. This page is market-entry research material, not legal, sanctions, export-control, registration-filing, or customs-clearance advice.